Emmanuel L.
- Country
- France
- Department
- Nephrology
Research Overview
- Randomized Multicenter Double-Blind Trial of Anakinra vs. Prednisone for Gout Flare in Chronic Kidney Disease Stages 3b-5 or Post-Transplant Patients
- Efficacy and Safety Assessment of Stiripentol in Patients Aged 6 and Older with Primary Hyperoxaluria Types 1, 2, or 3
- Randomized, Double-Blind, Multicenter Trial of Tocilizumab Versus Placebo in Refractory Chronic Inflammatory Chondrocalcinosis
Data & Insights
Has run more than one trial at 7 of 25 partner sites.
Specializations
Nephrology & Metabolic Disorders
This investigator specializes in treating patients with chronic kidney disease and related complications, with particular emphasis on renal transplantation and dialysis management.
- Advanced kidney disease (stages 3b-5)
- Renal transplant care
- Dialysis treatment
The research focus includes innovative therapeutic approaches for patients with compromised renal function.
Rheumatology
The investigator has developed expertise in managing gout and its complications, particularly in patients with concurrent kidney conditions. Their work explores novel therapeutic interventions using interleukin-1 antagonists.
- Gout flare management
- Anti-inflammatory treatments
- Complex case management
Special attention is given to treating rheumatologic conditions in patients with renal impairment.
Rare Diseases
The investigator focuses on rare metabolic disorders, particularly Primary Hyperoxaluria and its subtypes. Their work includes evaluation of novel therapeutic approaches for these challenging conditions.
- Primary Hyperoxaluria Types 1, 2, and 3
- Oxalate metabolism disorders
- Pediatric and adult metabolic conditions
Research interests encompass innovative treatments for rare metabolic disorders affecting kidney function.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.